Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Moolec Science's 3-Year RORE % for the quarter that ended in Dec. 2025 was -501.56%.
The industry rank for Moolec Science's 3-Year RORE % or its related term are showing as below:
MLEC's 3-Year RORE % is ranked worse than 99.23% of 1294
companies
in the Biotechnology industry
Industry Median: -11.54
vs MLEC: -501.56
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Moolec Science 3-Year RORE % Related Terms
Moolec Science 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Moolec Science's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLEC vs GNPX, ADIL, APVO: 3-Year RORE % Comparison
For the Biotechnology subindustry, Moolec Science's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moolec Science 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moolec Science's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Moolec Science's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Moolec Science (MLEC) has a 3-Year RORE % of -501.56 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Moolec Science and its competitors. According to the industry distribution chart, Moolec Science ranks #1284 out of 1294 companies in the Biotechnology industry, placing it in the top 99.2%.
Is Moolec Science's 3-Year RORE % too high?
Moolec Science's current 3-Year RORE % is -501.56. Based on the distribution chart, Moolec Science ranks #1284 out of 1294 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Moolec Science has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Moolec Science's 3-Year RORE % compare to GNPX and ADIL?
According to the Biotechnology industry distribution chart, Moolec Science ranks #1284 out of 1294 companies for 3-Year RORE %. This places Moolec Science in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Moolec Science and its competitors. Moolec Science's current 3-Year RORE % is -501.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moolec Science stock overvalued right now?
Based on GuruFocus' analysis, Moolec Science (MLEC) is currently considered Possible Value Trap. The stock's GF Value™ is $84.84, compared to a current price of $7.46 — trading 91.2% below its estimated fair value. The current 3-Year RORE % is -501.56. Moolec Science's overall GF Score™ is 46/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Moolec Science (MLEC), the current 3-Year RORE % is -501.56 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moolec Science (MLEC) Overvalued in 2026?
Based on GuruFocus' analysis, Moolec Science stock appears to be undervalued.
The current stock price of $7.46 is trading 91.2% below its estimated GF Value™ of $84.84.
GuruFocus considers Moolec Science to be Possible Value Trap.
Key valuation signals for MLEC:
3-Year RORE %: -501.56
GF Value™: $84.84 vs. price of $7.46 (91.2% below fair value)
No single metric tells the full story. See the MLEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.
46GF Score
Get the complete analysis for MLEC
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLEC has been successfully added to your 
